



VII CONGRESSO NAZIONALE **SOCIETÀ ITALIANA DI OSTEONCOLOGIA** 20-21 OTTOBRE 2022 ROMA

CON IL PATROCINIO DI



SAPIENZA
UNIVERSITÀ DI ROMA



SILVER

AMGEN

ICEA
CLINICAL BIOPHYSICS

IPSEN
Innovation for patient care

janssen **Oncology**
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

SYOWA KIRIN

MSD

NOVARTIS

BRONZE

MOLTENI
FARMACEUTICI




VII CONGRESSO NAZIONALE
SOCIETÀ ITALIANA DI OSTEONCOLOGIA


20-21 OTTOBRE 2022 ROMA

SAPIENZA UNIVERSITÀ DI ROMA

La Società Italiana di Osteoncologia (ISO) organizza il proprio congresso nazionale sui temi legati alla "salute dell'osso" nei pazienti oncologici. Uno degli scopi principali dell'ISO è promuovere la natura multidisciplinare dell'approccio clinico alla malattia scheletrica in oncologia, e le sue attività raccolgono inoltre in modo coerente tutti i dati degli esperti che contribuiscono alla salute dei pazienti con malattia scheletrica metastatica e metabolica. Il confronto interdisciplinare permetterà di sviscerare e chiarire tutti gli aspetti di un ambito che è diventato sempre più importante nella storia dei pazienti in termini di sopravvivenza a lungo termine. Oncologi, medici, chirurghi ortopedici, endocrinologi, radioterapisti, medici nucleari, radiologi interventisti e medici di cure palliative parteciperanno al congresso per fornire una prospettiva globale su questo tema, con l'obiettivo di fornire approfondimenti nel campo dell'osteoncologia.




Why is awareness of bone health in cancer so important ?



BONE METASTASES




- Epidemiological impact
- Clinical impact








Incidence of Bone Metastases by Cancer


Myeloma	70-95%
Breast	65-75%
Prostate	65-75%
Thyroid	60%
Bladder	40%
Lung	30-40%
Kidney	20-25%
Melanoma	15-45%

80% OF BONE METASTASES
BREAST, PROSTATE AND LUNG CANCER





SRES ARE PREVALENT IN PATIENTS WITH CANCER-ASSOCIATED BONE DISEASE



Data results from placebo arm of clinical trials.

NSCLC = Non-small cell lung cancer.

*Only 9-month data are available for surgical intervention and spinal cord compression in myeloma.

SREs HAVE ASSOCIATED DOWN-STREAM IMPLICATIONS



Pathological fracture

Extended healing time
Reduced survival^{1,2}
Loss of mobility
Need for care/ nursing home residence (especially hip fracture)³



Radiation to bone

Potential for 'pain flare' after therapy⁴
Myelosuppression⁵
Repeat visits for treating spinal cord compression⁶



Surgery to bone

Hospital stay
In-hospital mortality rate ~8%⁷
High rate of surgical complications^{7,8}
High failure rate; inability to restore function⁷



Spinal cord compression

Excruciating pain⁸
Need for steroidal medications⁸
Repeat visits for radiotherapy⁶
Irreversible paraparesis or paraplegia⁸
Loss of continence⁸

1. Gainor, Buchert. Clin Orthopaed Rel Res 1983;178:297–302; 2. Saad F et al. Cancer 2007;110:1860–7; 3. Poor et al. Osteoporos Int 1995;5:419–26; 4. Loblaw et al. Supp Care Cancer 2007;15:451–5; 5. Hellman, Krasnow. J Palliat Med 1998;1:277–83; 6. Maranzano et al. Tumori 2003;89:469–75; 7. Katzer et al. Arch Orthopaed Trauma Surg 2002;122:251–8; 8. Loblaw et al. J Clin Oncol 2005;23:2028–3.

TAKE HOME MESSAGE

Overview of Therapeutic Approaches to Address Metastatic Bone Disease

